The Bavarian-based biotechnology start-up, founded in 2019, develops novel medicines that leverage epigenetic mechanisms to address unmet clinical needs in genetically defined tumors. Using screening and cellular platforms, Eisbach Bio is able to create first-in-class inhibitors that directly target key vulnerabilities in cancer genomes, with a focus on chromatin regulatory mechanisms. The company's goal is to beat cancer at its own game by successfully targeting molecular vulnerabilities arising in cancer genomes.